Generic Name and Formulations:
Tetanus and reduced diphtheria toxoid, acellular pertussis vaccine (aluminum hydroxide adsorbed); susp for IM inj; preservative-free.
Indications for BOOSTRIX:
Diphtheria, tetanus, and pertussis booster immunization in patients ≥10 years of age.
Adults and Children:
<10yrs: not recommended. ≥10yrs (≥5yrs after last childhood DTwP or DTaP or adult Td vaccine): 0.5mL IM once into deltoid muscle.
Encephalopathy within 7 days after previous DTaP or DTwP vaccination.
Guillain-Barre syndrome (within 6 weeks) after previous tetanus toxoid vaccine: see literature. Progressive or unstable neurologic disorders (eg, cerebrovascular events, acute encephalopathic conditions). Previous Arthus-type hypersensitivity reaction: not recommended until ≥10yrs after prior dose of tetanus toxoid-containing vaccine. Immunosuppressed. Have epinephrine available. Latex allergy. Pregnancy (Cat.C). Nursing mothers.
Concomitant vaccines: see literature. Immunosuppressants (eg, radiation, chemotherapy, high-dose steroids): may get suboptimal response.
Local reactions (eg, pain), fever, headache, fatigue, GI upset.
Register pregnant patients exposed to Boostrix by calling (888) 452-9622. Report adverse events to VAERS by calling (800) 822-7967.
Vials (single dose)—10; Prefilled syringes (without needles)—1, 5, 10
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally